Skip to main content

Advertisement

Log in

Single-nucleotide polymorphisms p53 G72C and Mdm2 T309G in patients with psoriasis, psoriatic arthritis, and SAPHO syndrome

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Psoriasis (Ps), psoriatic arthritis (PsA), and SAPHO syndrome are diseases of unknown etiology that share common clinical features; however, family studies support the hypothesis of a genetic background for each of these diseases. To study the two common single-nucleotide polymorphisms (SNP) in the murine-double-minute-2-(Mdm2) and p53 genes in patients with Ps, PsA, and SAPHO syndrome. Genomic DNA was obtained from 187 patients with Ps, 50 with PsA, and 36 with SAPHO as well as 478 healthy controls. Mdm2-gene SNP T309G and p53-gene SNP G72C genotypes were determined by the polymerase chain reaction. Genotype and allele frequencies were analyzed with χ2-tests. Among the patients with Ps and PsA, no differences in allele or genotype frequencies of the p53-gene SNP G72C and Mdm2-gene SNP T309G were detected. However, in the SAPHO patients group, the frequencies of the Mdm2 SNP309 G allele and the genotype SNP 309 GG were significantly increased compared with the controls (G allele: 51.4 vs. 38.7%, P = 0.034; genotype GG: 36.1 vs. 14.2%, P = 0.002). In addition, the frequencies of the p53 SNP72 C allele and the genotype SNP 72 CC were also increased in the SAPHO patients cohort (C allele: 36.1 vs. 25.6%, P = 0.05; genotype CC: 16.7 vs. 6.3%, P = 0.05). SAPHO syndrome may be linked to an imbalance between MDM2 and p53 regulation with a “weak” p53-response associated with the Mdm2 SNP 309 G allele. In contrast, the p53 network does not seem to play a major role in pathogenesis of Ps or PsA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hannuksela-Svahn A, Pääkkö P, Autio P et al (1999) Expression of p53 protein before and after PUVA treatment in psoriasis. Acta Derm Venereol 79:195–199

    Article  CAS  PubMed  Google Scholar 

  2. Salvador G, Sanmarti R, Garcia-Peiró A et al (2005) p53 expression in rheumatoid and psoriatic arthritis synovial tissue and association with joint damage. Ann Rheum Dis 64:183–187

    Article  CAS  PubMed  Google Scholar 

  3. Chamot AM, Benhamou CL, Kahn MF et al (1987) Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey: 85 cases. Rev Rhum Mal Osteoartic 54:187–196

    CAS  PubMed  Google Scholar 

  4. Schilling F, Kessler S (2000) SAPHO syndrome: clinico-rheumatologic and radiologic differentiation and classification of a patient sample of 86 cases. Z Rheumatol 59:1–28

    Article  CAS  PubMed  Google Scholar 

  5. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307–310

    Article  CAS  PubMed  Google Scholar 

  6. Gudkov AV, Komarova EA (2007) Dangerous habits of a security guard: the two faces of p53 as a drug target. Hum Mol Genet 16:67–72

    Article  Google Scholar 

  7. Bond GL, Hu W, Bond EE, Robins H et al (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumour suppressor pathway and accelerates tumour formation in humans. Cell 119:591–602

    Article  CAS  PubMed  Google Scholar 

  8. Dumont P, Leu JI, Della Pietra AC 3rd et al (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365

    Article  CAS  PubMed  Google Scholar 

  9. Wright V, Moll JMH (1976) In: Seronegative Polyarthritis. North Holland Publishing Company, Amsterdam

  10. Assmann G, Wieczorek S, Wibisono D et al (2008) The p53 G72C and MDM2 T309G single nucleotide polymorphisms in patients with Wegener`s granulomatosis. Clin Exp Rheumatol 26:72–75

    Google Scholar 

  11. Butt C, Peddle L, Greenwood C et al (2006) Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case–control study. Arthritis Res Ther 8:R27

    Article  PubMed  Google Scholar 

  12. Gladman DD, Rahman P, Krueger GG et al (2008) Clinical and genetic registries in psoriatic disease. J Rheumatol 35:1458–1463

    CAS  PubMed  Google Scholar 

  13. Rahman P, Elder JT (2005) Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 64:ii37–ii39

    Article  PubMed  Google Scholar 

  14. Dumolard A, Gaudin P, Juvin R et al (1999) SAPHO syndrome or psoriatic arthritis? A familial case study. Rheumatology (Oxford) 38:463–467

    Article  CAS  Google Scholar 

  15. Queiro R, Moreno P, Sarasqueta C et al (2008) Synovitis-acne-pustulosis-hyperostosis-osteitis syndrome and psoriatic arthritis exhibit a different immunogenetic profile. Clin Exp Rheumatol 26:125–128

    CAS  PubMed  Google Scholar 

  16. Momand J, Wu HH, Dasgupta G (2000) MDM2-master regulator of the p53 tumor suppressor protein. Gene 242:15–29

    Article  CAS  PubMed  Google Scholar 

  17. Wawrzynow B, Zylicz A, Wallace M, Hupp T, Zylicz M (2007) MDM2 chaperones the p53 tumor suppressor. J Biol Chemistry 282:32603–32612

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We wish to thank A. Menzel (Luxemburg) for SNP genotyping. This study was supported by HOMFOR grants to GA and KR. GA, KR, TW, MP conceived and designed the study. GA, MM, ADW, CP contributed to the acquisition of the samples or study data by patients interview or chart reviews. GA and KR developed the statistical study design for this study and performed the statistical analysis. All authors were involved in the interpretation of the data. All authors read and approved the final manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gunter Assmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Assmann, G., Wagner, A.D., Monika, M. et al. Single-nucleotide polymorphisms p53 G72C and Mdm2 T309G in patients with psoriasis, psoriatic arthritis, and SAPHO syndrome. Rheumatol Int 30, 1273–1276 (2010). https://doi.org/10.1007/s00296-009-1136-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-009-1136-8

Keywords

Navigation